Immunological Aspects in Late Phase of Living Donor Liver Transplant Patients: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity

Table 1

Characteristics of the 49 patients.

Age	51 (20–69)
Male/female	33/16
Etiology of LDLT
HCV (HCC)	11 (6)
HBV (HCC)	11 (3)
NBNC (HCC)	10 (1)
PBC	6
Others	11
Median months after LDLT	54.6 (12.2–111.5)
Laboratory data
AST (U/L)	41.4 (14–257)
TB (mg/dL)	1.5 (0.3–3.7)
WBC (mm^−3)	6161 (2480–10480)
Dose of tacrolimus (mg/day)	2.3 (0.5–8)
Blood concentration of tacrolimus (ng/mL)	5.4 (0.4–10.3)
C/D ratio (ng/mL per mg/kg/day)	170.3 (40.3–599.5)

LDLT: living donor liver transplantation, HCV: hepatitis C virus, HCC: hepatocellular carcinoma, HBV: hepatitis B virus, PBC: primary biliary cirrhosis, LC: liver cirrhosis, FH: fulminant hepatitis, ALT: alanine aminotransferase, TB: total bilirubin, WBC: white blood cell count, C/D ratio: tacrolimus concentration/dose ratio.